Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan W Friedberg

Showing results (271-280 of 300) with videos related to

Pageof 30
Sort By:
Blood Advances|January 31, 2022
Improving eligibility criteria for first-line trials for patients with DLBCL using a US-based Delphi-method surveyR Andrew Harkins, Sharvil P Patel, Michelle J Lee, et al.
JAMA Oncology|March 1, 2019
Maintenance Therapies for Hodgkin and Non-Hodgkin Lymphomas After Autologous Transplantation: A Consensus Project of ASBMT, CIBMTR, and the Lymphoma Working Party of EBMTAbraham S Kanate, Ambuj Kumar, Peter Dreger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 27, 2020
Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt LymphomaMark Roschewski, Kieron Dunleavy, Jeremy S Abramson, et al.
Cancer|September 14, 2017
Outcomes in adolescents and young adults with Hodgkin lymphoma treated on US cooperative group protocols: An adult intergroup (E2496) and Children's Oncology Group (COG AHOD0031) comparative analysisTara O Henderson, Susan K Parsons, Kristen E Wroblewski, et al.
Blood|September 10, 2024
Real-world impact of differences in the WHO and ICC classifications of non-Hodgkin lymphoma: a LEO cohort study analysisBrooj Abro, Matthew J Maurer, Thomas M Habermann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 13, 2016
US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816Oliver W Press, Hongli Li, Heiko Schöder, et al.
Leukemia|February 19, 2026
Repression of miR-29 via MYC leads to increased CD40 signaling in transformed follicular lymphomaDaniel Filip, Katerina Litzmanova, Androniki Michaelou, et al.
The New England Journal of Medicine|December 14, 2021
Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell LymphomaHervé Tilly, Franck Morschhauser, Laurie H Sehn, et al.
Blood|May 31, 2024
Randomized study of induction with bendamustine-rituximab ± bortezomib and maintenance with rituximab ± lenalidomide for MCLMitchell R Smith, Opeyemi A Jegede, Peter Martin, et al.
Blood|September 25, 2025
PROs vs clinician-reported adverse events in a large clinical trial: findings from the phase 3 POLARIX studyCarrie Thompson, Marek Trněný, Franck Morschhauser, et al.
Pageof 30

Showing results (271-280 of 300) with videos related to

Sort By:
Pageof 30
Blood Advances|January 31, 2022
Improving eligibility criteria for first-line trials for patients with DLBCL using a US-based Delphi-method surveyR Andrew Harkins, Sharvil P Patel, Michelle J Lee, et al.
JAMA Oncology|March 1, 2019
Maintenance Therapies for Hodgkin and Non-Hodgkin Lymphomas After Autologous Transplantation: A Consensus Project of ASBMT, CIBMTR, and the Lymphoma Working Party of EBMTAbraham S Kanate, Ambuj Kumar, Peter Dreger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 27, 2020
Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt LymphomaMark Roschewski, Kieron Dunleavy, Jeremy S Abramson, et al.
Cancer|September 14, 2017
Outcomes in adolescents and young adults with Hodgkin lymphoma treated on US cooperative group protocols: An adult intergroup (E2496) and Children's Oncology Group (COG AHOD0031) comparative analysisTara O Henderson, Susan K Parsons, Kristen E Wroblewski, et al.
Blood|September 10, 2024
Real-world impact of differences in the WHO and ICC classifications of non-Hodgkin lymphoma: a LEO cohort study analysisBrooj Abro, Matthew J Maurer, Thomas M Habermann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 13, 2016
US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816Oliver W Press, Hongli Li, Heiko Schöder, et al.
Leukemia|February 19, 2026
Repression of miR-29 via MYC leads to increased CD40 signaling in transformed follicular lymphomaDaniel Filip, Katerina Litzmanova, Androniki Michaelou, et al.
The New England Journal of Medicine|December 14, 2021
Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell LymphomaHervé Tilly, Franck Morschhauser, Laurie H Sehn, et al.
Blood|May 31, 2024
Randomized study of induction with bendamustine-rituximab ± bortezomib and maintenance with rituximab ± lenalidomide for MCLMitchell R Smith, Opeyemi A Jegede, Peter Martin, et al.
Blood|September 25, 2025
PROs vs clinician-reported adverse events in a large clinical trial: findings from the phase 3 POLARIX studyCarrie Thompson, Marek Trněný, Franck Morschhauser, et al.
Pageof 30